RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation

Abstract

AbstractThe Ras-MAPK pathway is aberrantly regulated in cancer and developmental diseases called RASopathies. While typically the impact of Ras on the proliferation of various cancer cell lines is assessed, it is poorly established how Ras affects cellular differentiation.Here we implement the C2C12 myoblast cell line to systematically study the effect of Ras mutants and Ras-pathway drugs on differentiation. We first provide evidence that a minor pool of Pax7+ progenitors replenishes a major pool of transit amplifying cells that are ready to differentiate. Our data indicate that Ras isoforms have distinct roles in the differentiating culture, where K-Ras is more important than N-Ras to maintain the progenitor pool and H-Ras is significant for terminal differentiation. This assay could therefore provide significant new insights into Ras biology and Ras-driven diseases.In line with this, we found that all oncogenic Ras mutants block terminal differentiation of transit amplifying cells. Notably, while RASopathy K-Ras variants that are also NF1-GAP resistant also block differentiation, albeit less than their oncogenic counterparts. Profiling of targeted Ras-pathway drugs on oncogenic Ras mutants revealed their distinct abilities to restore normal differentiation as compared to triggering cell death. In particular, the MEK-inhibitor trametinib could broadly restore differentiation, while the mTOR-inhibitor rapamycin broadly suppressed differentiation.We expect that this quantitative assessment of the impact of Ras-pathway mutants and drugs on cellular differentiation has great potential to complement cancer cell proliferation data.